Merck’s ongoing pneumococcal vaccine development program is designed to provide options that address the specific needs of different populations, including infants and children, healthy adults ...

At the core of this is a recovery for its life science unit, which dipped last year as its boom from components for Covid ...

Merck CEO Rob Davis dubs Keytruda market exclusivity loss as 'more of a hill than a cliff' Meanwhile, in the U.S., the company’s pneumococcal conjugate vaccine Capvaxive recently scored a key ...

Citi analyst Geoff Meacham lowered the firm’s price target on Merck (MRK) to $130 from $140 and keeps a Buy rating on the shares ...

That shot protects against 21 types of the bacteria that cause pneumococcal disease, including eight not covered by other vaccines. Merck has said those eight account for more than one-quarter of ...

Vaccination with CAPVAXIVE may not protect all vaccine recipients. CAPVAXIVE is Merck’s approved 21-valent pneumococcal conjugate vaccine indicated for active immunization for the prevention of ...

The shots are also suggested for certain adults and children who are immunocompromised. A key panel of US health advisers voted in favor of lowering the age recommendation for vaccines made by ...

In June this year, the FDA approved Merck’s Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to protect against 21 strains of bacteria to prevent a severe form of pneumococcal disease.

Merck (NYSE:MRK) announced Wednesday that its 21-valent pneumococcal vaccine, Capvaxive, approved in the U.S. to prevent pneumonia, generated positive immune responses in a Phase 3 trial for ...

Merck reports Q3 sales of $16.7 billion, up 4% year-over-year, with Keytruda revenue rising 17%. EPS beats estimates; 2024 guidance updated on global demand shifts.